- Home
- ATOS vs HLP Comparison
ATOS vs HLP Comparison
Compare ATOS & HLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- HLP
- Stock Information
- Founded
- ATOS 2009
- HLP 2021
- Country
- ATOS United States
- HLP China
- Employees
- ATOS N/A
- HLP 167
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- HLP Industrial Machinery/Components
- Sector
- ATOS Health Care
- HLP Industrials
- Exchange
- ATOS Nasdaq
- HLP Nasdaq
- Market Cap
- ATOS 112.5M
- HLP 66.1M
- IPO Year
- ATOS 2012
- HLP 2023
- Fundamental
- Price
- ATOS $0.86
- HLP $0.84
- Analyst Decision
- ATOS Strong Buy
- HLP
- Analyst Count
- ATOS 4
- HLP 0
- Target Price
- ATOS $6.17
- HLP N/A
- AVG Volume (30 Days)
- ATOS 668.8K
- HLP 166.7K
- Earning Date
- ATOS 05-13-2025
- HLP 06-24-2025
- Dividend Yield
- ATOS N/A
- HLP N/A
- EPS Growth
- ATOS N/A
- HLP N/A
- EPS
- ATOS N/A
- HLP N/A
- Revenue
- ATOS N/A
- HLP $14,105,620.00
- Revenue This Year
- ATOS N/A
- HLP N/A
- Revenue Next Year
- ATOS N/A
- HLP N/A
- P/E Ratio
- ATOS N/A
- HLP N/A
- Revenue Growth
- ATOS N/A
- HLP N/A
- 52 Week Low
- ATOS $0.55
- HLP $0.72
- 52 Week High
- ATOS $1.66
- HLP $2.25
- Technical
- Relative Strength Index (RSI)
- ATOS 51.39
- HLP 38.28
- Support Level
- ATOS $0.84
- HLP $0.78
- Resistance Level
- ATOS $0.93
- HLP $0.96
- Average True Range (ATR)
- ATOS 0.06
- HLP 0.10
- MACD
- ATOS -0.00
- HLP -0.02
- Stochastic Oscillator
- ATOS 66.40
- HLP 20.15
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About HLP Hongli Group Inc.
Hongli Group Inc is a cold roll-formed steel profile manufacturer in China. It customizes and manufactures cold roll-formed steel profiles for machinery and equipment in a variety of sectors, including but not limited to mining and excavation, construction, agriculture, and transportation. Geographically, the company generates the majority of its revenue from the PRC.